PT  - JOURNAL ARTICLE
AU  - Elhalawani, Hesham
AU  - Cardenas, Carlos E.
AU  - Volpe, Stefania
AU  - Barua, Souptik
AU  - Stieb, Sonja
AU  - Rock, Calvin
AU  - Lin, Timothy
AU  - Yang, Pei
AU  - Wu, Haijun
AU  - Zaveri, Jhankruti
AU  - Elgohari, Baher
AU  - Abdallah, Lamiaa E.
AU  - Jethanandani, Amit
AU  - Mohamed, Abdallah S.R.
AU  - Court, Laurence E.
AU  - Hutcheson, Katherine A.
AU  - Gunn, G. Brandon
AU  - Rosenthal, David I.
AU  - Frank, Steven J.
AU  - Garden, Adam S.
AU  - Rao, Arvind
AU  - Fuller, Clifton D.
TI  - <sup>18</sup>FDG Positron Emission Tomography Mining for Metabolic Imaging Biomarkers of Radiation-induced Xerostomia in Patients with Oropharyngeal Cancer
AID  - 10.1101/2020.05.17.20104737
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.17.20104737
4099  - http://medrxiv.org/content/early/2020/05/21/2020.05.17.20104737.short
4100  - http://medrxiv.org/content/early/2020/05/21/2020.05.17.20104737.full
AB  - Purpose Head and neck cancers (HNC) radiotherapy (RT) is associated with inevitable injury to parotid glands and subsequent xerostomia. We investigated the utility of standardized uptake values (SUV) derived from routinely performed 18-fluorodeoxygluocose positron-emission tomography (18FDG-PET) to develop metabolic imaging biomarkers (MIBs) of RT-related parotid injury.Methods Data for oropharyngeal cancer (OPC) patients treated with RT at our institution between 2005-2015 with available planning computed tomography (CT), dose grid, pre- & first post-RT 18FDG-PET-CT scans, and physician-reported xerostomia assessment at 3-6 months post-RT (Xero 3-6ms) per CTCAE, was retrieved, following an IRB approval. A CT-CT deformable image co-registration followed by voxel-by-voxel resampling of pre & post-RT 18FDG activity and dose grid were performed. Ipsilateral (Ipsi) and contralateral (contra) parotid glands were sub-segmented based on the received dose in 5 Gy increments, i.e. 0-5 Gy, 5-10 Gy sub-volumes, etc. Median and dose-weighted SUV were extracted from whole parotid volumes and sub-volumes on pre- & post-RT PET scans, using in-house code that runs on MATLAB. Wilcoxon signed-rank and Kruskal-Wallis tests were used to test differences pre- and post-RT.Results 432 parotid glands, belonging to 108 OPC patients treated with RT, were sub-segmented & analyzed. Xero 3-6ms was reported as: non-severe (78.7%) and severe (21.3%). SUV- median values were significantly reduced post-RT, irrespective of laterality (p=0.02). A similar pattern was observed in parotid sub-volumes, especially ipsi parotid gland sub-volumes receiving doses 10-50 Gy (p<0.05). A Kruskal-Wallis test showed a significantly higher mean planned RT dose in the contra parotid in the patients with more severe Xero 3-6mo (p= 0.03). Multiple logistic regression showed a combined clinical-dosimetric-metabolic imaging model could predict the severity of Xero 3-6mo; AUC=0.78 (95%CI:0.66-0.85;p<0.0001)Conclusion We sought to quantify pre- and post-RT 18FDG-PET metrics of parotid glands in patients with OPC. Temporal dynamics of PET-derived metrics can potentially serve as MIBs of RT-related xerostomia in concert with clinical and dosimetric variables.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicable. Retrospective studyFunding StatementDr. Elhalawani was supported in part by the philanthropic donations from the Family of Paul W. Beach to Dr. G. Brandon Gunn, MD. Drs. Elhalawani and Fuller receive funding and project-relevant salary support from NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50 CA097007-10). This research is supported by the Andrew Sabin Family Foundation; Dr. Fuller is a Sabin Family Foundation Fellow. Drs. Fuller and Mohamed receive funding and project-relevant salary support from the National Institutes of Health (NIH), including the National Institute for Dental and Craniofacial Research Award (1R01DE025248-01/R56DE025248-01); National Cancer Institute (NCI) Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program(1R01CA218148-01); and National Science Foundation (NSF), Division of Mathematical Sciences; NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825-01). Dr. Fuller receive funding and project-relevant salary support from NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Program (R25EB025787). Dr. Fuller has received direct industry grant support and travel funding from Elekta AB. Dr. Fuller is supported via a National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679). Dr. Barua and Dr. Rao were supported by CCSG Bioinformatics Shared Resource P30 CA016672, CPRIT RP170719, CPRIT RP150578, NCI 1R37CA214955-01A1, a gift from Agilent technologies, and a Research Scholar Grant from the American Cancer Society (RSG-16-005-01). Dr. Elgohari is funded through joint supervision program by the Egyptian Ministry of Cultural and Higher Education. None of these industrial partners' equipment was directly used or experimented within the present work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe are currently working on anonymizing matched clinical and imaging datasets per HIPPA regulations prior to uploading the data to a public data repository